BioLineRx (BLRX) Enterprise Value (2010 - 2025)

BioLineRx's Enterprise Value history runs 16 years deep, the most recent figure standing at -$15.7 million for Q4 2025.

• On a quarterly basis, Enterprise Value rose 19.6% year-over-year to -$15.7 million in Q4 2025; TTM through Dec 2025 was -$15.7 million, a 19.6% increase from a year earlier, with the FY2025 full-year figure at -$15.7 million, up 19.6% from the prior year.
• Enterprise Value grew to -$15.7 million in Q4 2025 per BLRX's latest filing, from -$25.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$15.7 million in Q4 2025 and bottomed at -$65.6 million in Q2 2021.
• The 5-year median for Enterprise Value is -$41.5 million (2023), against an average of -$40.1 million.
• Across the five-year window, Enterprise Value tumbled 198.67% in 2021 and soared 54.65% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$57.1 million in 2021, then gained by 10.59% to -$51.1 million in 2022, then climbed by 15.83% to -$43.0 million in 2023, then surged by 54.5% to -$19.6 million in 2024, then rose by 19.6% to -$15.7 million in 2025.
• Per Business Quant, the three latest BLRX Enterprise Value figures stand at -$15.7 million (Q4 2025), -$25.2 million (Q3 2025), and -$28.2 million (Q2 2025).